title: Ceruloplasmin prevents hemostatic disorders during experimental hyperammonemia.
abstract: Experimental hyperammonemia in rats was accompanied by hemostatic disorders manifesting in coagulopathy (activation of the intrinsic pathway of blood coagulation) and suppression of platelet function. Ceruloplasmin in a total dose of 60 mg/kg effectively normalized coagulation hemostasis and functional activity of platelets by improving secretory processes in platelets and increasing aggregation rate.
authors.affiliation: Department of Pathophysiology, Chelyabinsk State Medical Academy. mvo2003@list.ru
authors.forename: M V
authors.initials: MV
authors.lastname: Osikov
authors.forename: E V
authors.initials: EV
authors.lastname: Makarov
authors.forename: L V
authors.initials: LV
authors.lastname: Krivokhizhina
mesh_terms: D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D002113:Calcification, Physiologic / Q000187:drug effects; D002570:Ceruloplasmin / Q000627:therapeutic use*; D005340:Fibrinogen / Q000378:metabolism; D020141:Hemostatic Disorders / Q000139:chemically induced* / Q000517:prevention & control*; D022124:Hyperammonemia / Q000150:complications*; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D051381:Rats; D013918:Thrombin Time
chemical_list: D005340:Fibrinogen; D002570:Ceruloplasmin